FDA Okays RAS Inhibitor Daraxonrasib for Pancreatic Cancer

Daraxonrasib is being hailed as a potential game changer for metastatic pancreatic cancer, roughly doubling survival vs chemotherapy in previously treated patients. Medscape Medical News